Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Schmidt K; von Haehling S; Doehner W; Palus S; Anker SD; Springer J
  • Source:
    Journal of cachexia, sarcopenia and muscle [J Cachexia Sarcopenia Muscle] 2011 Jun; Vol. 2 (2), pp. 105-109. Date of Electronic Publication: 2011 May 08.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders Country of Publication: Germany NLM ID: 101552883 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2190-5991 (Print) Linking ISSN: 21905991 NLM ISO Abbreviation: J Cachexia Sarcopenia Muscle
    • Publication Information:
      Publication: 2015- : Berlin : John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders
      Original Publication: Heidelburg : Springer-Verlag
    • Abstract:
      BACKGROUND: A hallmark symptom of cancer cachexia is the loss of skeletal muscle. This is at least partially due to a deregulation of the growth hormone/IGF-1 axis and a subsequently impaired protein synthesis in skeletal muscle. Here, we investigated the effect of IGF-1 supplementation in a rat model of cancer cachexia. METHODS: Juvenile rats were inoculated with the Yoshida AH-130 hepatoma and treated once daily with 0.3 mg kg(-1) day(-1) (low dose) or 3 mg kg(-1) day(-1) (high dose) IGF-1 or placebo for a period of maximal 16 days. Body weight and body composition (by NMR) were assessed at baseline and at the end of the study or day of death. Locomotor activity and food intake were assessed at baseline and day 10/11 after tumour inoculation for 24 h. RESULTS: Untreated tumour-bearing rats lost 55.3 ± 2.14 g body weight, which was reduced by low-dose to -39.6 ± 11.1 g (p = 0.0434) and high-dose IGF-1 to -42.7 ± 8.8 g (p = 0.057). Placebo-treated rats lost 41.4 ± 2.0-g lean mass, which was attenuated by low-dose IGF-1 (-28.8 ± 8.3 g, p = 0.041) and high-dose IGF-1 (-30.9 ± 7.4, p = 0.067). Spontaneous activity and food intake were improved by low-dose IGF-1 only. No effect on fat mass was observed. Low-dose IGF-1 significantly reduced mortality (HR = 0.45, 95%CI = 0.21-0.93, p = 0.0315), whilst the high dose did not reach significance (HR = 0.68, 95%CI = 0.26-1.74, p = 0.42). CONCLUSION: Low-dose IGF-1 reduced mortality and attenuated loss of body weight as well as muscle mass in the Yoshida hepatoma rat model. Moreover, an improved quality of life was observed in these animals. Further experiments using different doses are necessary.
    • References:
      J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):1-5. (PMID: 21475699)
      Horm Res. 2006;65 Suppl 1:28-34. (PMID: 16508331)
      Cell. 2010 Aug 20;142(4):531-43. (PMID: 20723755)
      J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):177-185. (PMID: 21475694)
      Int J Cardiol. 2009 Apr 17;133(3):388-93. (PMID: 19246111)
      Front Biosci (Landmark Ed). 2011 Jan 01;16:1233-60. (PMID: 21196229)
      Am J Clin Nutr. 2010 Apr;91(4):1143S-1147S. (PMID: 20164318)
      Acta Paediatr Suppl. 1999 Feb;88(428):182-4. (PMID: 10102077)
      Growth Regul. 1993 Mar;3(1):40-4. (PMID: 7683526)
      Nat Cell Biol. 2001 Nov;3(11):1009-13. (PMID: 11715022)
      Biochem Pharmacol. 1970 Apr;19(4):1387-97. (PMID: 4327763)
      Am J Physiol. 1992 Mar;262(3 Pt 2):R426-31. (PMID: 1373040)
      Neurobiol Dis. 2001 Aug;8(4):541-54. (PMID: 11493020)
      J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):7-8. (PMID: 21475697)
      J Cachexia Sarcopenia Muscle. 2010 Sep;1(1):9-21. (PMID: 21475693)
      Lymphokine Cytokine Res. 1993 Aug;12(4):219-23. (PMID: 8218594)
      Int J Cancer. 2010 Oct 1;127(7):1706-17. (PMID: 20039316)
      CA Cancer J Clin. 2007 Jul-Aug;57(4):225-41. (PMID: 17626119)
      Clin Cancer Res. 2007 Mar 1;13(5):1356-61. (PMID: 17332276)
      Am J Physiol Regul Integr Comp Physiol. 2006 Sep;291(3):R674-83. (PMID: 16614058)
      Cell. 2004 Apr 30;117(3):399-412. (PMID: 15109499)
      Langenbecks Arch Surg. 2001 Mar;386(2):132-40. (PMID: 11374046)
    • Publication Date:
      Date Created: 20110719 Latest Revision: 20191120
    • Publication Date:
      20201019
    • Accession Number:
      PMC3117996
    • Accession Number:
      21766056
  • Citations
    • ABNT:
      SCHMIDT, K. et al. IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. Journal of cachexia, sarcopenia and muscle, [s. l.], v. 2, n. 2, p. 105–109, 2011. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=21766056. Acesso em: 31 out. 2020.
    • AMA:
      Schmidt K, von Haehling S, Doehner W, Palus S, Anker SD, Springer J. IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. Journal of cachexia, sarcopenia and muscle. 2011;2(2):105-109. Accessed October 31, 2020. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=21766056
    • APA:
      Schmidt, K., von Haehling, S., Doehner, W., Palus, S., Anker, S. D., & Springer, J. (2011). IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2(2), 105–109.
    • Chicago/Turabian: Author-Date:
      Schmidt, Katja, Stephan von Haehling, Wolfram Doehner, Sandra Palus, Stefan D Anker, and Jochen Springer. 2011. “IGF-1 Treatment Reduces Weight Loss and Improves Outcome in a Rat Model of Cancer Cachexia.” Journal of Cachexia, Sarcopenia and Muscle 2 (2): 105–9. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=21766056.
    • Harvard:
      Schmidt, K. et al. (2011) ‘IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia’, Journal of cachexia, sarcopenia and muscle, 2(2), pp. 105–109. Available at: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=21766056 (Accessed: 31 October 2020).
    • Harvard: Australian:
      Schmidt, K, von Haehling, S, Doehner, W, Palus, S, Anker, SD & Springer, J 2011, ‘IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia’, Journal of cachexia, sarcopenia and muscle, vol. 2, no. 2, pp. 105–109, viewed 31 October 2020, .
    • MLA:
      Schmidt, Katja, et al. “IGF-1 Treatment Reduces Weight Loss and Improves Outcome in a Rat Model of Cancer Cachexia.” Journal of Cachexia, Sarcopenia and Muscle, vol. 2, no. 2, June 2011, pp. 105–109. EBSCOhost, search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=21766056.
    • Chicago/Turabian: Humanities:
      Schmidt, Katja, Stephan von Haehling, Wolfram Doehner, Sandra Palus, Stefan D Anker, and Jochen Springer. “IGF-1 Treatment Reduces Weight Loss and Improves Outcome in a Rat Model of Cancer Cachexia.” Journal of Cachexia, Sarcopenia and Muscle 2, no. 2 (June 2011): 105–9. http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=21766056.
    • Vancouver/ICMJE:
      Schmidt K, von Haehling S, Doehner W, Palus S, Anker SD, Springer J. IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia. Journal of cachexia, sarcopenia and muscle [Internet]. 2011 Jun [cited 2020 Oct 31];2(2):105–9. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdc&AN=21766056